Literature DB >> 1351523

DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells.

S J Falk1, P J Smith.   

Abstract

This study addressed the potential radiosensitizing and DNA-damaging actions of the DNA topoisomerase I poison camptothecin (CPT) on SV40 transformed normal (MRC5CVI) and ataxia-telangiectasia (AT5BIVA) fibroblast cell lines. In both cell lines CPT induced a dose-dependent delay of cells in S phase, followed by a dose-dependent trapping in G2/M phase. Acute X-irradiation produced patterns of G2/M arrest and S-phase delay similar to those observed for CPT in the MRC5CVI cell line, but no S phase delay was observed in the AT5BIVA cell line consistent with the ataxiatelangiectasia phenotype of this cell line. X-irradiation of CPT-treated cells resulted in additive prolongation of S phase delay in MRC5CVI cultures and additive effects for cell killing in both cell lines. The potential for topoisomerase I-DNA cross-linking by CPT was not altered by 24h pretreatment with CPT, or by acute X-irradiation. Hypersensitivity of AT5BIVA to CPT was not attributable to elevated levels of complex trapping. These findings suggest that in a rapidly proliferating human tumour there is unlikely to be synergistic therapeutic gain when the two agents are used concurrently, and that previously reported radiosensitization by CPT is restricted to G0 phase cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1351523     DOI: 10.1080/09553009214551601

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  7 in total

1.  Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma.

Authors:  Hanan Ahmed Wahba; Hend Ahmed El-Hadaad; Sameh Roshdy
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.

Authors:  J P Lamond; M P Mehta; D A Boothman
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

Review 3.  Multilevel therapeutic targeting by topoisomerase inhibitors.

Authors:  P J Smith; S Souès
Journal:  Br J Cancer Suppl       Date:  1994-09

4.  Purification of GidA protein, a novel topoisomerase II inhibitor produced by Streptomyces flavoviridis.

Authors:  Antony K Teresa Infanta S; S D Nisshanthini; M Palaniswamy; J Angayarkanni
Journal:  World J Microbiol Biotechnol       Date:  2013-08-31       Impact factor: 4.253

5.  A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.

Authors:  R Glynne-Jones; S Falk; T S Maughan; H M Meadows; D Sebag-Montefiore
Journal:  Br J Cancer       Date:  2007-01-30       Impact factor: 7.640

6.  Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.

Authors:  K Tamura; M Takada; I Kawase; T Tada; S Kudoh; K Okishio; M Fukuoka; N Yamaoka; Y Fujiwara; M Yamakido
Journal:  Jpn J Cancer Res       Date:  1997-02

7.  Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments].

Authors:  A Yokoyama; Y Kurita; N Saijo; T Tamura; K Noda; K Shimokata; T Matsuda
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.